TY - JOUR
T1 - Lung cancer symptoms at diagnosis
T2 - Results of a nationwide registry study
AU - Ruano-Raviña, Alberto
AU - Provencio, Mariano
AU - Calvo De Juan, Virginia
AU - Carcereny, Enric
AU - Moran, Teresa
AU - Rodriguez-Abreu, Delvys
AU - López-Castro, Rafael
AU - Cuadrado Albite, Eugenio
AU - Guirado, María
AU - Gómez González, Lucía
AU - Massutí, Bartomeu
AU - Ortega Granados, Ana Laura
AU - Blasco, Ana
AU - Cobo, Manuel
AU - Garcia-Campelo, Rosario
AU - Bosch, Joaquim
AU - Trigo, José
AU - Juan, Óscar
AU - Aguado De La Rosa, Carlos
AU - Dómine, Manuel
AU - Sala, María
AU - Oramas, Juana
AU - Casal-Rubio, Joaquín
AU - Cerezo, Sara
N1 - Publisher Copyright:
© 2020 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.
PY - 2020/11/19
Y1 - 2020/11/19
N2 - Background Lung cancer is currently the leading cause of cancer death. Despite its high incidence and mortality, there are few studies describing its symptoms at diagnosis broken down by tumour stage and tobacco use. Accordingly, this study was proposed to describe the frequency of the most common symptoms of non-small cell lung cancer and small cell lung cancer (SCLC) at diagnosis, with a breakdown by stage and tobacco use. Patients and methods Cases were collected from the Spanish Thoracic Tumour Registry, a nationwide registry sponsored by the Spanish Lung Cancer Group. More than 50 hospitals recruited histologically confirmed lung cancer cases and information was gathered through personal interview plus data contained in the electronic clinical record. There were no data available on the lag between the appearance of the first symptoms and diagnosis of lung cancer. Results A total of 9876 patients (74% male, median age 64 years) were recruited from 2016 to 2019. Of these, 12.5% presented with SCLC. Stage IV was the most frequent stage at diagnosis (46.6%), and the most frequent symptom was cough (33.9%), followed by dyspnoea (26.7%). No symptom was present in 59% of patients diagnosed in stage I; 40% of stage I patients presented with at least one symptom, while 27.7% of patients in stage IV had no symptoms at diagnosis. Cough was the most frequent symptom in SCLC (40.6%), followed by dyspnoea (34.3%). The number of symptoms was similar across the respective smoking categories in SCLC, and differences between the symptoms analysed did not exceed 7% in any case. Conclusion The absence of the most frequent symptoms (ie, cough, pain, dyspnoea) should not lead to a decision to rule out the presence of lung cancer. A relevant percentage of stage IV patients displayed no symptoms at diagnosis.
AB - Background Lung cancer is currently the leading cause of cancer death. Despite its high incidence and mortality, there are few studies describing its symptoms at diagnosis broken down by tumour stage and tobacco use. Accordingly, this study was proposed to describe the frequency of the most common symptoms of non-small cell lung cancer and small cell lung cancer (SCLC) at diagnosis, with a breakdown by stage and tobacco use. Patients and methods Cases were collected from the Spanish Thoracic Tumour Registry, a nationwide registry sponsored by the Spanish Lung Cancer Group. More than 50 hospitals recruited histologically confirmed lung cancer cases and information was gathered through personal interview plus data contained in the electronic clinical record. There were no data available on the lag between the appearance of the first symptoms and diagnosis of lung cancer. Results A total of 9876 patients (74% male, median age 64 years) were recruited from 2016 to 2019. Of these, 12.5% presented with SCLC. Stage IV was the most frequent stage at diagnosis (46.6%), and the most frequent symptom was cough (33.9%), followed by dyspnoea (26.7%). No symptom was present in 59% of patients diagnosed in stage I; 40% of stage I patients presented with at least one symptom, while 27.7% of patients in stage IV had no symptoms at diagnosis. Cough was the most frequent symptom in SCLC (40.6%), followed by dyspnoea (34.3%). The number of symptoms was similar across the respective smoking categories in SCLC, and differences between the symptoms analysed did not exceed 7% in any case. Conclusion The absence of the most frequent symptoms (ie, cough, pain, dyspnoea) should not lead to a decision to rule out the presence of lung cancer. A relevant percentage of stage IV patients displayed no symptoms at diagnosis.
KW - Lung cancer
KW - Smoking
KW - Symptoms
KW - Lung cancer
KW - Smoking
KW - Symptoms
KW - Lung cancer
KW - Smoking
KW - Symptoms
UR - http://www.scopus.com/inward/record.url?scp=85096457645&partnerID=8YFLogxK
U2 - 10.1136/esmoopen-2020-001021
DO - 10.1136/esmoopen-2020-001021
M3 - Article
C2 - 33214227
AN - SCOPUS:85096457645
SN - 2059-7029
VL - 5
JO - ESMO Open
JF - ESMO Open
IS - 6
M1 - e001021
ER -